JGC
ABOS icon

J. Goldman & Co’s Acumen Pharmaceuticals ABOS Stock Holding History

J. Goldman & Co’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62,986
Closed -$303K – 351
2023
Q2 		$303K Sell
62,986
-72,014
-53% -$345K 0.01% 313
2023
Q1 		$548K Buy
+135,000
New +$705K 0.02% 261

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

J. Goldman & Co's ABOS Position: Q3 2023 in Review

J. Goldman & Co sold out of Acumen Pharmaceuticals (ABOS) in Q3 2023, closing a stake of 62,986 shares — an estimated $303K sold.

J. Goldman & Co first reported a position in ABOS in Q1 2023 and held it in 2 quarters. The position peaked at $548K in Q1 2023. 66 funds tracked by Wall St. Rank hold ABOS as of Q3 2023.

  • J. Goldman & Co reported no remaining Acumen Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • J. Goldman & Co sold 62,986 Acumen Pharmaceuticals shares in Q3 2023, an estimated $303K.
  • J. Goldman & Co first reported a position in Acumen Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • J. Goldman & Co's Acumen Pharmaceuticals position peaked at $548K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.